In this video we discuss the results of the NSABP B-35 trial of anastrozole vs tamoxifen in postmenopausal women with DCIS who had undergone lumpectomy plus radiation therapy.
In this interview Dr. Armitage discusses his early career and what led him to specialize in the treatment of lymphoma, and shares his thoughts on the future of cancer treatment.
In this interview we discuss the impact of the Affordable Care Act (ACA) on health disparities, as well as the challenges the law will present for physicians.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
Dr. Katz describes how he uses social media to learn more about patient perceptions of cancer, how to decide which social media to use, and drawbacks to using social media in a professional capacity.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Dr. Aisner discusses some of the key ways oncologists can work better with pathologists at their institutions.
In this interview, Dr. Hyman Muss discusses some of the barriers to providing high-quality care to geriatric cancer patients, including the barriers to diagnosis and treatment.
Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.